Unity Biotechnology reports Q4 EPS (50c) vs. (28c) last year

Cash, cash equivalents and marketable securities totaled $23.2M as of December 31, 2024 compared with $43.2M as of December 31, 2023. Unity believes that current cash, cash equivalents and marketable securities are sufficient to fund operations into the fourth quarter of 2025. “We expect to receive 24-week topline data from our Phase 2b ASPIRE study in diabetic macular edema in this quarter,” said Anirvan Ghosh, Ph.D., CEO of Unity. “DME remains a significant unmet need, and we believe UBX1325 has the potential to provide a differentiated treatment option for patients who continue to experience vision loss despite current standard-of-care therapies. With its novel mechanism of action and durable therapeutic profile, UBX1325 could offer meaningful advantages over existing anti-VEGF treatments. The 24-week data as well as the 36-week data will be instrumental in shaping our plans for a potential pivotal trial and advancing our program.”